Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-661 + Ivacaftor in Cystic Fibrosis (Homozygous F508del)
NCT02508207Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Feb 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tezacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Feb 2016; status: completed.
02
Drugs
tezacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02508207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02508207.